141 related articles for article (PubMed ID: 37878195)
1. Recovery of suspended reimbursements of high-cost drugs subjected to monitoring registries and negotiated agreements (MEAs): a tool for governance and clinical appropriateness in the Italian reality.
Capuozzo M; Celotto V; Zovi A; Langella R; Ferrara F
Eur J Health Econ; 2024 Feb; 25(1):1-5. PubMed ID: 37878195
[TBL] [Abstract][Full Text] [Related]
2. The Italian experience with the use of monitoring registers attached to negotiated agreements (MEAs) of the Italian Medicines Agency is a tool for governance and clinical appropriateness.
Capuozzo M; Celotto V; Ottaiano A; Zovi A; Langella R; Ferrara F
J Cancer Policy; 2023 Dec; 38():100450. PubMed ID: 37922982
[TBL] [Abstract][Full Text] [Related]
3. MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITY.
Montilla S; Xoxi E; Russo P; Cicchetti A; Pani L
Int J Technol Assess Health Care; 2015 Jan; 31(4):210-3. PubMed ID: 26646859
[TBL] [Abstract][Full Text] [Related]
4. Financial Outcomes of Managed Entry Agreements for Pharmaceuticals in Italy.
Trotta F; Guerrizio MA; Di Filippo A; Cangini A
JAMA Health Forum; 2023 Dec; 4(12):e234611. PubMed ID: 38153808
[TBL] [Abstract][Full Text] [Related]
5. The Evolution of AIFA Registries to Support Managed Entry Agreements for Orphan Medicinal Products in Italy.
Xoxi E; Facey KM; Cicchetti A
Front Pharmacol; 2021; 12():699466. PubMed ID: 34456724
[TBL] [Abstract][Full Text] [Related]
6. Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency.
Villa F; Tutone M; Altamura G; Antignani S; Cangini A; Fortino I; Melazzini M; Trotta F; Tafuri G; Jommi C
Health Policy; 2019 Jun; 123(6):595-600. PubMed ID: 31097207
[TBL] [Abstract][Full Text] [Related]
7. [Medicines use in Italy. 2020 OsMed National Report.].
Zito S; Fortinguerra F; Pierantozzi A; Ambrosino F; Traversa G; Trotta F; Da Cas R; Cangini A
Recenti Prog Med; 2021 Oct; 112(10):659-667. PubMed ID: 34647536
[TBL] [Abstract][Full Text] [Related]
8. [Mutational oncology of lung cancer: molecular markers, drugs, negotiation conditions and experiences in national reference centers.].
Esposito I; Calabria S; Piccinni C; Addesi A; Dondi L; Ronconi G; Pedrini A; Maggioni AP; Curigliano G; Listi A; Righi L; Novello S; Buglioni S; Ciliberto G; Pruneri G; Martini N
Recenti Prog Med; 2021 Jun; 112(6):419-437. PubMed ID: 34128934
[TBL] [Abstract][Full Text] [Related]
9. Critical Care Network in the State of Qatar.
Hijjeh M; Al Shaikh L; Alinier G; Selwood D; Malmstrom F; Hassan IF
Qatar Med J; 2019; 2019(2):2. PubMed ID: 31763205
[TBL] [Abstract][Full Text] [Related]
10. [Establishing the value of new drugs in Italy.].
Villa F; Jommi C; Altamura G; Antignani S; Cangini A; Fortino I; Melazzini M; Trotta F; Tafuri G
Recenti Prog Med; 2020 Feb; 111(2):65-69. PubMed ID: 32089554
[TBL] [Abstract][Full Text] [Related]
11. Current national initiatives about drug policies and cost control in Europe: the Italy example.
Rocchi F; Addis A; Martini N;
J Ambul Care Manage; 2004; 27(2):127-31. PubMed ID: 15069990
[TBL] [Abstract][Full Text] [Related]
12. [About direct and on behalf delivery of drugs.].
De Rosa MM
Recenti Prog Med; 2022 Dec; 113(12):705-714. PubMed ID: 36420846
[TBL] [Abstract][Full Text] [Related]
13. Progress on drug pricing negotiations in China.
Tang M; Song P; He J
Biosci Trends; 2020 Jan; 13(6):464-468. PubMed ID: 31875587
[TBL] [Abstract][Full Text] [Related]
14. Managed Entry Agreements: Policy Analysis From the European Perspective.
Dabbous M; Chachoua L; Caban A; Toumi M
Value Health; 2020 Apr; 23(4):425-433. PubMed ID: 32327159
[TBL] [Abstract][Full Text] [Related]
15. Promoting Access to Innovative Anticancer Medicines: A Review of Drug Price and National Reimbursement Negotiation in China.
Mingge X; Jingyu W; Qi L; Zhe Z; Qing R
Inquiry; 2023; 60():469580231170729. PubMed ID: 37171066
[TBL] [Abstract][Full Text] [Related]
16. National Recovery and Resilience Plan and Health: qualitative analysis on the sustainability of the interventions on healthcare.
Cascini F; Gentili A
Ann Ig; 2023; 35(5):602-610. PubMed ID: 36866601
[TBL] [Abstract][Full Text] [Related]
17. The last decade of Italian pharmaceutical policy: instability or consolidation?
Fattore G; Jommi C
Pharmacoeconomics; 2008; 26(1):5-15. PubMed ID: 18088155
[TBL] [Abstract][Full Text] [Related]
18. Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden.
Ferrario A; Kanavos P
Soc Sci Med; 2015 Jan; 124():39-47. PubMed ID: 25461860
[TBL] [Abstract][Full Text] [Related]
19. Funds Reimbursement of High-Cost Drugs in Gastrointestinal Oncology: An Italian Real Practice 1 Year Experience at the National Cancer Institute of Naples.
Capozzi M; De Divitiis C; Ottaiano A; Teresa T; Capuozzo M; Maiolino P; Botti G; Tafuto S; Avallone A;
Front Public Health; 2018; 6():291. PubMed ID: 30370266
[No Abstract] [Full Text] [Related]
20. CHARACTERISTICS OF MANAGED ENTRY AGREEMENTS IN AUSTRALIA.
Robinson MF; Mihalopoulos C; Merlin T; Roughead E
Int J Technol Assess Health Care; 2018 Jan; 34(1):46-55. PubMed ID: 29277174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
